<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794919</url>
  </required_header>
  <id_info>
    <org_study_id>2022-BE-QBHSGFSP-04</org_study_id>
    <nct_id>NCT05794919</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets in Chinese Healthy Volunteers</brief_title>
  <official_title>Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets and Calcium Hydroxybenzene Sulfonate Tablets (Doxium®) Under Fed Conditions in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hainan Linheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the bioequivalence of two Calcium Hydroxybenzene&#xD;
      Dispersible Tablets in healthy Chinese volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial preparation is Calcium Hydroxybenzene Sulphonate Dispersible Tablets produced by&#xD;
      Hainan Linheng Pharmaceutical Co., Ltd.&#xD;
&#xD;
      The reference preparation is Calcium Hydroxybenzene Sulphonate Tablets (Doxium ®) produced by&#xD;
      OM pharma S.A.&#xD;
&#xD;
      The bioequivalence of two preparations will be evaluated at the fast or fed conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2023</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax</measure>
    <time_frame>Pharmacokinetic plasma samples collected over 36 hour period</time_frame>
    <description>Cmax - Maximum Observed Concentration in Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC 0-t</measure>
    <time_frame>Pharmacokinetic plasma samples collected over 36 hour period</time_frame>
    <description>Area Under the Concentration-time Curve From Time Zero to Time of Last</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioequivalence based on AUC 0-∞</measure>
    <time_frame>Pharmacokinetic plasma samples collected over 36 hour period</time_frame>
    <description>Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>Calcium Hydroxybenzene Sulphonate Dispersible Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The healthy subjects will be administered a single dose of Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g under fast or fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxium®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The healthy subjects will be administered a single dose of Doxium® 250mg under fast or fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Hydroxybenzene Sulphonate Dispersible Tablets 0.25g</intervention_name>
    <description>A generic product manufactured by Hainan Linheng Pharmaceutical Co., Ltd.</description>
    <arm_group_label>Calcium Hydroxybenzene Sulphonate Dispersible Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Hydroxybenzene Sulfonate Tablets（Doxium®) 250mg</intervention_name>
    <description>Calcium Hydroxybenzene Sulfonate Tablets（Doxium®）produced by OM pharma S.A.</description>
    <arm_group_label>Doxium®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participate voluntarily and sign an informed consent form before the study;&#xD;
&#xD;
          2. Age: 18 to 55 years old (including 18 and 55 years old) , male and female;&#xD;
&#xD;
          3. Weight: female subjects with weight ≥45.0kg, male subjects with weight ≥50.0kg, with&#xD;
             the body mass index of 19.0~28.0 kg/m (including 19.0 and 28.0);&#xD;
&#xD;
          4. The physical examination, vital signs, laboratory examination and electrocardiogram&#xD;
             are not abnormal or abnormal but with no clinical significance;&#xD;
&#xD;
          5. Have no pregnancy plan and appropriate contraceptive measures during the trial and&#xD;
             within 6 months after the last dose.&#xD;
&#xD;
          6. Be able to communicate well, understand and comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Be allergic, or have a clear history of allergies to trial drugs and excipients;&#xD;
&#xD;
          2. Have diseases in circulatory system, respiratory system, digestive system, hematologic&#xD;
             system, nervous system, immune system, urinary system, endocrine system and mental&#xD;
             system, or have medical history of the above-mentioned systems and other diseases that&#xD;
             may significantly affect drug absorption, distribution, metabolism and excretion.&#xD;
&#xD;
          3. Have a history of drug abuse or are positive for urine durg screening;&#xD;
&#xD;
          4. Pregnant or lactating women, or serum HCG positive for female subjects, or there was a&#xD;
             unprotected sex within 2 weeks before screening;&#xD;
&#xD;
          5. Frequent smokers and alcoholics within the first 3 months (smoking more than 5&#xD;
             cigarettes/day on average, drinking an average of more than 21 units of alcohol per&#xD;
             week, 1 unit = 360 mL beer or 45 mL liquor or 150 mL wine), or cannot stop using any&#xD;
             tobacco products, or unable to stop alcohol intake during the whole research;&#xD;
&#xD;
          6. Have donated more than 400 mL of blood within 3 months before screening, or lost more&#xD;
             than 400 mL of blood for other reasons, or donated plasma within 14 days before&#xD;
             screening;&#xD;
&#xD;
          7. Have used any prescription drugs, vaccines, Chinese herbal medicine within 4 weeks&#xD;
             before first dose of the research drug, and/or use any over-the-counter drugs (OTC),&#xD;
             vitamins, nutritional supplements within 2 weeks before first dose of the research&#xD;
             drug;&#xD;
&#xD;
          8. Have participated in any clinical trial within 3 months before screening;&#xD;
&#xD;
          9. Refuse to stop using any methylxanthine drinks or foods such as coffee, tea, cola,&#xD;
             chocolate, or drinks containing grapefruit, or any food that affect the activity of&#xD;
             liver enzymes from 48 hours before the first dose of the research drug to the end of&#xD;
             the study;&#xD;
&#xD;
         10. Have undergone surgery within 6 months before screening, or plan to receive a surgery&#xD;
             recently ;&#xD;
&#xD;
         11. Have abnormality or clinical significance in any infection screening;&#xD;
&#xD;
         12. Have special requirements on diet and cannot accept unified diet;&#xD;
&#xD;
         13. Have the difficulty in venous blood taking or can not tolerate venipuncture, or have a&#xD;
             history of dizziness in blood taking;&#xD;
&#xD;
         14. Any other condition that researchers believe unsuitable for enrolling into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Feng Wu, Dr</last_name>
    <phone>0086-10-58268486</phone>
    <email>trdrug@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institue for Drug Clinical Trials</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu, Dr</last_name>
      <phone>0086-10-58268486</phone>
      <email>trdrug@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Phenol</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

